There are more than 8,700 pharmaceutical enterprises in China, more than 6,000 pharmaceutical manufacturers through GMP, more than 3,000 API manufacturers registered with the State Food and Drug Administration, and a large proportion of pharmaceutical intermediates.
In 2008, the total import and export volume of China's APIs was US$23.894 billion, up 22.19% year-on-year, accounting for 49.07% of the total import and export of China's medicines.
From 2008 to now, China's raw material drug exports have an average annual compound growth rate of more than 20%, and 2009 exports reached US$17.58 billion, a year-on-year increase of 29.59%. The export of the API industry is becoming more and more obvious and important, which directly promotes the improvement of the industry's profit level. From January to November 2012, the raw material medicine realized a profit of 15.59 billion yuan, an increase of 49.5%.